Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma with portal venous invasion (Q82449382)

From Wikidata

Jump to navigation Jump to search

scientific article published on 09 November 2011

Language	Label	Description	Also known as
English	Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma with portal venous invasion	scientific article published on 09 November 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22072099%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma with portal venous invasion (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22072099%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

pegylated interferon

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Kazuhiro Kasai

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22072099%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Akira Ushio

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22072099%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Yukiho Kasai

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22072099%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Kei Sawara

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22072099%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Yasuhiro Miyamoto

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22072099%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Kanta Oikawa

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22072099%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Hidekatsu Kuroda

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22072099%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Yasuhiro Takikawa

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22072099%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Kazuyuki Suzuki

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22072099%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

publication date

9 November 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22072099%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22072099%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

118

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22072099%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22072099%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

3302-3310

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22072099%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26648

7 January 2021

based on heuristic

inferred from DOI database lookup

Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26648

7 January 2021

based on heuristic

inferred from DOI database lookup

Natural history of untreated nonsurgical hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26648

7 January 2021

based on heuristic

inferred from DOI database lookup

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26648

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26648

7 January 2021

based on heuristic

inferred from DOI database lookup

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26648

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26648

7 January 2021

based on heuristic

inferred from DOI database lookup

Repeated arterial infusion chemotherapy for inoperable hepatocellular carcinoma using an implantable drug delivery system

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26648

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26648

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26648

7 January 2021

based on heuristic

inferred from DOI database lookup

Biomedical and biotechnological applications of PEG- and PM-modified proteins

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26648

7 January 2021

based on heuristic

inferred from DOI database lookup

Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26648

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of newly developed combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon alpha-2b for advanced hepatocellular carcinoma with portal venous invasion: preliminary results

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26648

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26648

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26648

7 January 2021

based on heuristic

inferred from DOI database lookup

Design and endpoints of clinical trials in hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26648

7 January 2021

based on heuristic

inferred from DOI database lookup

Development of portal vein invasion and its outcome in hepatocellular carcinoma treated by transcatheter arterial chemo-embolization

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26648

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatocellular carcinoma with portal vein tumor thrombosis: clinical characteristics, prognosis, and patient survival analysis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26648

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatocellular carcinoma and portal vein invasion: results of treatment with transcatheter oily chemoembolization

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26648

7 January 2021

based on heuristic

inferred from DOI database lookup

A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26648

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatic arterial infusion of 5-fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus of the portal vein

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26648

7 January 2021

based on heuristic

inferred from DOI database lookup

Stimulation of 5-fluorouracil metabolic activation by interferon-alpha in human colon carcinoma cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26648

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon effects upon fluorouracil metabolism by HL-60 cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26648

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26648

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon-alpha delays S-phase progression in human hepatocellular carcinoma cells via inhibition of specific cyclin-dependent kinases.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26648

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of several species of human leukocyte interferon on cytotoxic activity of NK cells and monocytes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26648

7 January 2021

based on heuristic

inferred from DOI database lookup

Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26648

7 January 2021

based on heuristic

inferred from DOI database lookup

Identification of the major positional isomer of pegylated interferon alpha-2b

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26648

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26648

7 January 2021

based on heuristic

inferred from DOI database lookup

Apoptosis- and necrosis-inducing potential of cladribine, cytarabine, cisplatin, and 5-fluorouracil in vitro: a quantitative pharmacodynamic model.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26648

7 January 2021

based on heuristic

inferred from DOI database lookup

Intra-arterial therapy with cisplatin suspension in lipiodol and 5-fluorouracil for hepatocellular carcinoma with portal vein tumour thrombosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26648

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.26648

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22072099%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22072099%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q82449382&oldid=1780613657"